Objective: To monitor the effect of intravit real injection of Bevacizumab on intraocular pressure to know whether intraocular pressure-lowering medication or paracentesis is required prophylactically or after that. Study Design: Case series. Place and Duration of Study: Department of Ophthalmology, Isra University Hospital, Hyderabad, from May to Oct 2019. Methodology: A total 90 eyes of patients with proliferative diabetic retinopathy and exudative age-related macular degeneration, received intravitreal injection of Bevacizumab. Intraocular pressure was recorded with a Goldman applantaion tonometer at baseline, and then after a procedure at 5 minutes, 30 minutes, 1 hour and 1 week. The patients' age, gender, disease, intraocular pressure, history of glaucoma, previous surgery, phakic status, topical and systemic medications were recorded. Results: The mean baseline intraocular pressure was 13.54 ± 2.1mmHg in proliferative diabetic retinopathy and 12.76 ± 1.8mmHg in exudative age-related macular degeneration (p-value 0.091). The mean intraocular pressure elevation following intravitreal Bevacizumab at 5 minutes was 32.89 ± 6.3mmHg and 32.18 ± 5.7mmHg (p-value 0.592), at 30 minutes was 16.71 ± 2.6mmHg and 15.53 ± 2.4mmHg (p-value 0.036), at one hour was 14.20 ± 2.0mmHg and 13.47 ± 1.9mmHg (p-value 0.098) and at one week 13.82 ± 1.7mmHg and 13.06 ± 1.7mmHg (p-value 0.051) in proliferative diabetic retinopathy and exudative agerelated macular degeneration respectively. There was no significant difference between the two diseases. Conclusion: There is an abrupt and transient rise in the intraocular pressure following intravitreal injection of Bevacizumab, but it did not remain elevated for longer duration; hence there was no need for intraocular pressure lowering medication and paracentesis.